Martine Walmsley
f8martine.bsky.social
Martine Walmsley
@f8martine.bsky.social
PSC | Coeliac | IBD | Patient Advocate
Involve patients in your research!
Head of Research Strategy PSC Support😁
she/her
Reposted by Martine Walmsley
We welcome this important research from @icrlondon.bsky.social & St Mark's Hospital. They've found a way to predict #BowelCancer risk in people with #InflammatoryBowelDisease.

This could help guide treatment & colonoscopy frequency and may lead to more personalised care for those with #PSC-IBD
February 7, 2025 at 12:07 PM
Reposted by Martine Walmsley
Starting to come up with ideas for #20kyourway #pscsupport #LiverSky #PSC
December 30, 2024 at 4:17 PM
Reposted by Martine Walmsley
🎆Research granted🎆

Grants always carry a sense of responsibility, but receiving one from a patient organization takes this to a whole new level

PSC Support decided to support our project Multiomics data for personalised PSC prognosis

#PSCSupport #AI
#Personnalised_medicine #Hepatology
January 20, 2025 at 8:17 AM
Reposted by Martine Walmsley
2025 is the perfect year to take your career to the next level🚀

There are also 6 positions to fill in the EASL Scientific Committee, Policy Public Health and Advocacy Committee, Ethics and Compliance Committee and Nurses & AHPs Task Force.

Apply by 20 January: easl.eu/leadership25

#LiverSky
January 15, 2025 at 9:34 AM
Reposted by Martine Walmsley
Welcome to BlueSky Martine Walmsley, Head of Research Strategy PSC Support @f8martine.bsky.social.

Check out our growing PSC Starter Pack (I've added you!) go.bsky.app/6hLJsJT Please suggest any new PSC people to add.

#PSC
January 10, 2025 at 4:40 PM
Reposted by Martine Walmsley
New work from us:
Oral vancomycin is associated with attenuation in IBD activity in people with PSC. We also studied changes in gut microbiome profile, and key transcriptomic and metabolomic features.

academic.oup.com/ecco-jcc/adv...
Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
AbstractBackground. We conducted a single-arm interventional study, to explore mucosal changes associated with clinical remission under oral vancomycin (OV
academic.oup.com
December 14, 2024 at 1:18 PM
Reposted by Martine Walmsley
Pleased that #FARGO - a randomised, multicentre, placebo-controlled phase IIa trial of #FMT to treat #PSC - is running and recruiting. Have a look at the protocol paper out now in #BMJOpen: doi.org/10.1136/bmjo... @pscsupport.bsky.social @cholestasisdoc.bsky.social
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
Introduction Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven...
doi.org
January 7, 2025 at 7:30 AM